Volume 8 Issue 5, May 2023

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 8 Issue 5, May 2023:
Letter
Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
Miner Shao,Jie Yao,Yunke Wang,Lufeng Zhao,Baizhou Li,Lili Li,Zuqun Wu,Zexin Chen,Junqiang Fan &…Fuming Qiu  ORCID: orcid.org/0000-0001-5793-1023